Navigation Links
New Biomarkers Study Could Lead to Better Malaria Vaccine Design
Date:4/27/2011

SEATTLE, April 27, 2011 /PRNewswire/ -- In the first study of its type in the malaria field, Seattle BioMed has been awarded an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity. Ruobing Wang, M.D., Ph.D., will lead the study – Seattle BioMed's first to include the integration of its recently announced systems biology approach to infectious disease research – with a team that includes Seattle BioMed's Stefan Kappe, Ph.D., and Alan Aderem, Ph.D., along with Patrick Duffy, M.D., of the National Institutes of Health, Jonathan Derry, Ph.D., of Sage Bionetworks, and Xiaowu Liang, Ph.D., of Antigen Discovery Inc. (ADi).

According to Wang, the goal of the study is to identify and validate biomarkers that correlate with vaccine-induced protective immunity against malaria infection. "In order to bring the burden of malaria under control – with the ultimate goal of eradicating the pathogens that cause disease – we know we need a highly efficacious anti-infection vaccine," she explained. "But, without reliable biomarkers of anti-infection immunity, the development and testing of malaria vaccines is a slow and expensive process." Biomarkers will be used for prediction and monitoring the vaccine efficacy in clinical trials and to select optimal vaccine candidates for development.

To conduct this research, Seattle BioMed will call upon its proven areas of expertise and knowledge – successful vaccine and immunology studies in animal models of malaria, the ability to grow human malaria parasites in mosquitoes for research and clinical studies, and its ability to develop genetically attenuated parasite strains for human trials. It will also begin full-scale trials in its Malaria Clinical Trials Center, and employ its newfound expertise in the area of systems biology.

Through Kappe's research, Seattle BioMe
'/>"/>

SOURCE Seattle Biomedical Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
2. Reportlinker Adds Biomarkers - Technologies, Markets and Companies
3. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
4. Reportlinker Adds Biomarkers - Technologies, Markets And Companies
5. Biomarkers in Late Stage Clinical Trials: Applications, Opportunities and Activities of Leading Players
6. LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue
7. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
8. Reportlinker Adds Biomarkers - Technologies, Markets and Companies
9. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
10. Frost & Sullivan Reveals Strategies on Turning Challenges into Opportunities in the European Biomarkers Market
11. Data on WaferGens SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 SoundConnect , an ... is proud to announce the addition of Adobe ... Connect’s elearning tools to quickly deploy and manage ... training tools for desktop and mobile learning solutions. ... the perfect online training solution, enabling organizations to ...
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... County Representatives Unveil State-of-the-Art Facility ... ... Officials from Novavax,Inc. (Nasdaq: NVAX ), the State ... new state-of-the-art vaccine production,facility at the company,s headquarters in Rockville, ...
... Total Revenues of $62.0 Million, Up 55 Percent over First Quarter ... 2007, - First ... Before Non-Cash Charges of $1.13 per Basic Share, ... per Diluted Share, SILVER SPRING, Md., May 1 United Therapeutics,Corporation (Nasdaq: UTHR ) ...
... Strategic Transactions Increase EUSA,s Focus on Late-Stage and Marketed ... ... Products, DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 ,EUSA ... pain control and critical care, today announced that,it has divested ...
Cached Biology Technology:Novavax Opens Its First U.S. Vaccine Plant 2Novavax Opens Its First U.S. Vaccine Plant 3Novavax Opens Its First U.S. Vaccine Plant 4United Therapeutics Reports First Quarter 2008 Financial Results 2United Therapeutics Reports First Quarter 2008 Financial Results 3United Therapeutics Reports First Quarter 2008 Financial Results 4United Therapeutics Reports First Quarter 2008 Financial Results 5United Therapeutics Reports First Quarter 2008 Financial Results 6United Therapeutics Reports First Quarter 2008 Financial Results 7EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... pleased to announce its new relationship with the International ... CINP will partner to publish International Journal of ... journal. , Alan Frazer, Editor-in-Chief of IJNP ... of OUP will further facilitate the goal for the ... leading journals within neuropsychopharmacology. The conversion of the ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2
... a research team from the National Institute of Standards ... has shown how to detect and monitor the tiny ... of an atomic force microscope probe, and in so ... of the instruments measurements under ambient conditions. Their recently ...
... have learned to manipulate the proportion of females and ... mapped the entire genome of a bacterium that infects ... published in PNAS, reveal extremely high frequencies of gene ... it is hoped that it will be possible to ...
... DC, March 25, 2009 - Critically endangered hawksbill turtles ... the Dominican Republic after a powerful government campaign cracked ... 99 percent of these souvenirs have been withdrawn or ... A 2006 survey carried out by TRAFFIC found ...
Cached Biology News:Making a point: Picoscale stability in a room-temperature AFM 2Gene exchange common among sex-manipulating bacteria 2Turtles no longer turned into souvenirs 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: